Mesenchymal stem cells for the treatment of CNS diseases

Patent metadata

Field	Value
Publication number	US-9474787-B2
Application number	US-201414556281-A
Country	US
Kind code	B2
Filing date	Dec 1, 2014
Priority date	May 28, 2008
Publication date	Oct 25, 2016
Grant date	Oct 25, 2016

Abstract

An isolated human cell is disclosed comprising at least one mesenchymal stem cell phenotype and secreting brain-derived neurotrophic factor (BDNF), wherein a basal secretion of the BDNF is at least five times greater than a basal secretion of the BDNF in a mesenchymal stem cell. Methods of generating same and uses of same are also disclosed.

First claim

What is claimed is:

1. An isolated non-genetically modified human cell differentiated ex vivo from a mesenchymal stem cell under conditions such that the isolated non-genetically modified human cell expresses at least one mesenchymal stem cell marker and secretes brain-derived neurotrophic factor (BDNF) and glial derived neurotrophic factor (GDNF), and does not secrete nerve growth factor (bNGF), wherein said at least one mesenchymal stem cell marker is selected from the group consisting of CD73, CD90 and CD105, wherein a basal secretion of said GDNF is at least two times greater than a basal secretion of said GDNF in a non-differentiated, non-genetically modified human mesenchymal stem cell.

2. The isolated human cell of claim 1 , further expressing at least one additional neurotrophic factor.

3. The isolated human cell of claim 2 , wherein said at least one additional neurotrophic factor is selected from the group consisting of neurotrophin-3 (NT-3), neurotrophin-4/5, neurturin (NTN), persephin, artemin (ART), ciliary neurotrophic factor (CNTF), insulin growth factor-I (IGF-1) and neublastin.

4. The isolated human cell of claim 1 , wherein said conditions are such that the isolated human cell takes up at least ten times more glutamate from its surroundings than a non-differentiated, non-genetically modified mesenchymal stem cell.

5. A pharmaceutical composition comprising the isolated non-genetically modified human cell of claim 1 as an active agent and a pharmaceutically acceptable carrier.

Assignees

• Ramot At Tel-Aviv Univ Ltd
• Brainstorm Cell Therapeutics Ltd

Inventors

• Kadouri Avinoam
• Bar-Ilan Avihay
• Melamed Eldad
• Offen Daniel
• Sadan Ofer
• Bahat-Stromza Merav

Classifications

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P25/02

  for peripheral neuropathies · CPC title

• A61K35/12

  Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00) · CPC title

• C12N2501/115

  Basic fibroblast growth factor (bFGF, FGF-2) · CPC title

• C12N2501/11

  Epidermal growth factor [EGF] · CPC title